aTyr Pharma
ATYR
25 hedge funds and large institutions have $26.3M invested in aTyr Pharma in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 5 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
15% more capital invested
Capital invested by funds: $22.9M → $26.3M (+$3.43M)
9% more funds holding
Funds holding: 23 → 25 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20.93% less ownership
Funds ownership: 57.84% → 36.92% (-21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$663K |
| 3 |
TI
Telemetry Investments
New York
|
+$556K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$267K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$213K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$1.29M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$470K |
| 3 |
Renaissance Technologies
New York
|
-$363K |
| 4 |
Two Sigma Advisers
New York
|
-$333K |
| 5 |
Two Sigma Investments
New York
|
-$182K |
ATYR Hedge Fund Activity: Q1 2021 in Review
25 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2021, worth a combined $26.3M — up 15% from $22.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ATYR positions and 5 closed out — a net gain of 2 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $1M. The largest seller was Altium Capital Management, exiting entirely with an estimated $1.29M sold.
- 25 institutional investors held aTyr Pharma (ATYR) as of Q1 2021, up from 23 in Q4 2020.
- Funds reported $26.3M of aTyr Pharma stock for Q1 2021, up 15% quarter-over-quarter.
- 7 funds opened new aTyr Pharma positions in Q1 2021 and 5 closed out, a net change of +2 holders.
- The largest aTyr Pharma buyer in Q1 2021 was BlackRock, an estimated $1M added.
- The largest aTyr Pharma seller in Q1 2021 was Altium Capital Management, an estimated $1.29M sold.
Based on aggregated 13F filings for Q1 2021.